CellEDIT Service represents a novel workflow leveraging FluidFM-mediated intranuclear nanoinjection of CRISPR/Cas9 components into single cells. Control of the amount and stoichiometry of RNP ...

Cytosurge AG, a Swiss company that develops, manufactures and distributes scientific high-precision nanotechnology instruments and robotic systems based on its patented FluidFM® technology, and Bruker ...

Olympus Europe and Cytosurge have partnered in order to accelerate common innovation of next-generation tools for single cell experiments and to expand the distribution of the versatile FluidFM BOT ...

A new peer-reviewed study validates CellEDIT’s ability to overcome cell-editing barriers, uncovering dermokine’s pivotal role in wound healing ...

The first FluidFM User Conference organized by Cytosurge has been a complete success – this was the feedback of our attendees. From Thursday, 31st January, to Friday, 1st February 2019, more than 50 ...

Cytosurge AG, a leader in single-cell manipulation, and Lexogen, a pioneer in RNA sequencing solutions, have announced their partnership to advance live-cell sequencing (Live-seq). The collaboration ...

FluidFM offers unique advantages in simultaneous three-dimensional manipulation and mechanical measurements of a wide range of materials at the micro- and nanoscale, including biological specimens, ...

CellEDIT Service represents a novel workflow leveraging FluidFM-mediated intranuclear nanoinjection of CRISPR/Cas9 components into single cells. Control of the amount and stoichiometry of RNP ...